Home/GenSight Biologics/José-Alain Sahel

JS

José-Alain Sahel

Scientific Founder

GenSight Biologics

Therapeutic Areas

Ophthalmology Neurodegenerative Diseases

GenSight Biologics Pipeline

Drug	Indication	Phase
GS010 (Lenadogene Nolparvovec / Lumevoq)	Leber Hereditary Optic Neuropathy (LHON) due to ND4 mutation	Phase 3
GS030	Retinitis Pigmentosa (RP)	Phase 1/2

Leadership Team at GenSight Biologics

Laurence Rodriguez

Chief Executive Officer

Jan Eryk Umiastowski

Chief Financial Officer

Chief Medical Officer

Chief Technical Officer

Scientific Founder

View full GenSight Biologics profile